Zymeworks Inc (ZYME)

Currency in USD
14.81
+0.24(+1.65%)
Real-time Data·
ZYME Scorecard
Full Analysis
Management has been aggressively buying back shares
ZYME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.5714.98
52 wk Range
9.0317.70
Key Statistics
Prev. Close
14.57
Open
14.57
Day's Range
14.57-14.98
52 wk Range
9.03-17.7
Volume
76.27K
Average Volume (3m)
456.19K
1-Year Change
27.92%
Book Value / Share
4.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZYME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.89
Upside
+47.80%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Zymeworks Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Zymeworks Inc Company Profile

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Zymeworks Inc Earnings Call Summary for Q2/2025

  • Revenue surged to $48.7M in Q2 2025, up from $19.2M in Q2 2024, driven by milestone payments and deferred revenue recognition
  • Net income reached $2.3M, reversing a $37.7M loss from Q2 2024; cash resources increased to $333.4M with runway into 2027
  • Stock declined 2.01% in aftermarket trading; analyst price targets range from $12 to $30, suggesting potential upside
  • Company expects increased royalty revenues from zanadatumab approvals; top-line data from Horizon GEA-1 study due Q4 2025
  • EPS forecasts range from -$0.29 to -$0.52 USD; revenue projections between $18.1M and $30.81M for upcoming quarters
Last Updated: 08/08/2025, 11:56
Read Full Transcript

Compare ZYME to Peers and Sector

Metrics to compare
ZYME
Peers
Sector
Relationship
P/E Ratio
−14.9x−0.5x−0.6x
PEG Ratio
−0.410.010.00
Price/Book
3.3x2.4x2.6x
Price / LTM Sales
8.9x7.6x3.3x
Upside (Analyst Target)
50.5%81.1%39.0%
Fair Value Upside
Unlock24.7%4.9%Unlock

Analyst Ratings

8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.89
(+47.80% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
0.03 / -0.45
Revenue / Forecast
48.73M / --
EPS Revisions
Last 90 days

ZYME Income Statement

People Also Watch

38.10
EXEL
+0.53%
48.42
PTCT
-1.79%
19.80
INVA
+0.20%
16.73
OPRA
+4.04%
188.69
IQV
+0.36%

FAQ

What Stock Exchange Does Zymeworks Trade On?

Zymeworks is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Zymeworks?

The stock symbol for Zymeworks is "ZYME."

What Is the Zymeworks Market Cap?

As of today, Zymeworks market cap is 1.11B.

What Is Zymeworks's Earnings Per Share (TTM)?

The Zymeworks EPS (TTM) is -0.98.

From a Technical Analysis Perspective, Is ZYME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Zymeworks Stock Split?

Zymeworks has split 0 times.

How Many Employees Does Zymeworks Have?

Zymeworks has 273 employees.

What is the current trading status of Zymeworks (ZYME)?

As of 26 Aug 2025, Zymeworks (ZYME) is trading at a price of 14.81, with a previous close of 14.57. The stock has fluctuated within a day range of 14.57 to 14.98, while its 52-week range spans from 9.03 to 17.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.